Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1273MR)

This product GTTS-WQ1273MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1273MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2733MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ3673MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ2966MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ14699MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ8221MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ4390MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ7305MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ6955MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW